Takeda financials show growth as post-Weber era looms

30 January 2025

Japanese drugmaker Takeda’s (TYO: 4502) latest financial results were presented Thursday, though they took a back seat to the news that the group’s long-term chief executive Christophe Weber is to retire in 2026.

He has been credited with leading a major transformation in his 12-year reign at Takeda, which has announced results after the third quarter of Japan’s financial year, along with forecasts for the year as a whole.

Revenue for the first three quarters grew by nearly 10% to 3,528.2 billion yen ($22.83 billion), while operating profit for the nine-month period was 417.5 billion yen, up 86%. 

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical